|CD261||TNFRSF10a (tumor necrosis factor receptor superfamily, member 10a), TRAIL-R1, DR4|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 1 glycoprotein
|50 / 50|
|CD261 is widely expressed. High levels of expression are found on some tumor cells, lymphoid and gut tissues, activated T cells, peripheral blood leukocytes, small intestine, thymus, K562 erythroleukemia cells amd MCF7 breast carcinoma cells and very weak on leukocyte cells. |
|MOLECULAR FAMILY NAME: Belongs to the tumor necrosis factor receptor family.|
CD261 is a single-pass type-1 468 aa glycoprotein. It contains a 23 aa signal sequence, a 216 aa extracellular domain containing 3 TNFR cysteine-rich repeats and 1 potential N-glycosylation site, a 23 aa transmembrane domain and a 206 aa cytoplasmic domain containing a intracellular death domain.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
POST-TRANSLATIONAL MODIFICATION: No information.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD261|
CD261 binds CD253 (TNFSF10).
|CD261 acts as a ligand for CD253 (TRAIL). CD261 contains a cytoplasmic death domain (DR4), which mediates the apoptosis of sensitive cells via the adaptor molecule FADD and caspase-8. FADD binds DR4 and recruits caspase-8, which initates a sequence of events that leads ro cell death. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand CD253 and thus transduces cell death signal and induces cell apoptosis. |
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD261 IN INTACT ANIMAL
A polymorphism in CD261 has been associated with the risk of bladder cancer.
PROTEIN AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD261: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD261: No information.
For further information see Griffith, T. S. et al (1999) J. Immunol. 162: 2597-2605.
Database accession numbers
Revised June 25, 2008